TEVA PHARMACEUTICAL INDUSTRIES LTD

For the period ended Dec 31, 2025. Filed Feb 3, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 3, 2026

TEVA$42.97+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of income

(U.S. dollars in millions, except share and per share data)

	Year ended December 31,
	2025	2024	2023
Net revenues	$17,258	$16,544	$15,846
Cost of sales	8,320	8,481	8,200
Gross profit	8,938	8,064	7,645
Research and development expenses, net	1,013	998	953
Selling and marketing expenses	2,686	2,541	2,336
General and administrative expenses	1,287	1,161	1,162
Intangible assets impairments	259	251	350
Goodwill impairment	—	1,280	700
Other asset impairments, restructuring and other items	1,050	1,388	718
Legal settlements and loss contingencies	467	761	1,043
Other loss (income)	18	(14)	(49)
Operating income (loss)	2,157	(303)	433
Financial expenses – net	934	981	1,057
Income (loss) before income taxes	1,223	(1,284)	(624)
Income taxes (benefit)	(180)	676	(7)
Share in (profits) losses of associated companies – net	(15)	(1)	(2)
Net income (loss)	1,418	(1,959)	(615)
Net income (loss) attributable to redeemable and non-redeemable non-controlling interests	7	(320)	(56)
Net income (loss) attributable to Teva	1,410	(1,639)	(559)
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$1.23	$(1.45)	$(0.50)
Diluted	$1.21	$(1.45)	$(0.50)
Weighted average number of shares (in millions):
Basic	1,145	1,131	1,119
Diluted	1,163	1,131	1,119

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.